Home/Filings/4/0001818382-24-000186
4//SEC Filing

Sebelius Kathleen 4

Accession 0001818382-24-000186

CIK 0001818382other

Filed

Sep 10, 8:00 PM ET

Accepted

Sep 11, 5:53 PM ET

Size

13.6 KB

Accession

0001818382-24-000186

Insider Transaction Report

Form 4
Period: 2024-09-10
Transactions
  • Sale

    Common Stock

    2024-09-10$5.39/sh1,548$8,34441,207 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-09-102,4796,021 total
    Exercise: $3.35From: 2024-08-15Exp: 2033-06-15Common Stock (2,479 underlying)
  • Exercise/Conversion

    Common Stock

    2024-09-10$4.34/sh+4,521$19,62143,910 total
  • Exercise/Conversion

    Stock Options (right to buy)

    2024-09-104,5213,979 total
    Exercise: $4.34From: 2024-08-09Exp: 2032-06-09Common Stock (4,521 underlying)
  • Exercise/Conversion

    Common Stock

    2024-09-10$3.35/sh+2,479$8,30542,755 total
  • Sale

    Common Stock

    2024-09-10$5.41/sh3,634$19,66040,276 total
Footnotes (2)
  • [F1]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Humacyte, Inc.

CIK 0001818382

Entity typeother

Related Parties

1
  • filerCIK 0001654316

Filing Metadata

Form type
4
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 5:53 PM ET
Size
13.6 KB